Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)
Clinical Infectious Diseases · 06.10.2025 · 81 (3) · 634-644
DOI: 10.1093/cid/ciae596 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 04.12.2024. Verfasst von Doug Arbetter und 14 weiteren Autor:innen. Beteiligte Einrichtung: Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Respiratory Tract Infections, Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, Sanofi.
Abstract (Originalsprache)
Background
Nirsevimab is an extended half-life, highly potent, anti-respiratory syncytial virus (RSV) fusion protein neutralizing monoclonal antibody with efficacy against RSV-associated medically attended (MA) lower respiratory tract infection (LRTI) in infants and medically vulnerable children (aged ≤24 months). This post hoc exploratory analysis examined the incidence of LRTI from RSV and other respiratory pathogens during MELODY: a 2:1 randomized, double-blind, placebo-controlled, phase 3 study of nirsevimab in healthy term and late preterm (ie, gestational age ≥35 weeks) infants entering their first RSV season.
Methods
A total of 3012 participants were randomized to nirsevimab (n = 2009) or placebo (n = 1003). Nasopharyngeal swabs were collected from infants who presented with an LRTI and tested for 22 different respiratory pathogens using the BioFire® Respiratory 2.1 Panel. Incidence of RSV and non-RSV MA-LRTIs through day 511 and LRTI severity were assessed.
Results
A total of 852 nasopharyngeal swabs were collected from 561 participants through day 511: 519 swabs from 337 nirsevimab participants and 333 swabs from 224 placebo participants. RSV and non-RSV infections were detected in 193 of 852 (22.7%) and 55 of 852 (64.7%) swabs, respectively. RSV infection rates were lower with nirsevimab compared with placebo, including RSV–rhinovirus/enterovirus coinfections. Rates of other viral infections were similar between study arms. Approximately 70% of single RSV infections and RSV coinfections were adjudicated as mild, and 26.2% of single RSV infections and 24.5% of RSV coinfections required hospitalization.
Conclusions
Nirsevimab protected against RSV single and coinfections, with no evidence of replacement of RSV with other respiratory viruses. Clinical Trials Registration. NCT03979313.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, USA.
- Bioinformatics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
- Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
- Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
- Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences of the Ben-Gurion University of the Negev, Beer-Sheva, Israel.
- Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
ORCID-Profile: Doug Arbetter, Vancheswaran Gopalakrishnan, Ron Dagan, Xavier Saez-Llorens, Elizabeth J Kelly
Förderung
- AstraZeneca
- Sanofi
Zitieren
APA
Arbetter, D., Gopalakrishnan, V., Aksyuk, A. A., Ahani, B., Chang, Y., Dagan, R., Esser, M. T., Hammitt, L. L., Mankad, V. S., Saez-Llorens, X., Shen, D., Leach, A., Kelly, E. J., Villafana, T., & Wilkins, D. (2025). Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY). Clinical Infectious Diseases, 81(3), 634-644. https://doi.org/10.1093/cid/ciae596
Vancouver
Arbetter D, Gopalakrishnan V, Aksyuk AA, Ahani B, Chang Y, Dagan R, et al. Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY). Clinical Infectious Diseases. 2025;81(3):634-644. doi:10.1093/cid/ciae596
BibTeX
@article{Arbetter2025,
author = {Arbetter, Doug and Gopalakrishnan, Vancheswaran and Aksyuk, Anastasia A and Ahani, Bahar and Chang, Yue and Dagan, Ron and Esser, Mark T and Hammitt, Laura L and Mankad, Vaishali S and Saez-Llorens, Xavier and Shen, David and Leach, Amanda and Kelly, Elizabeth J and Villafana, Tonya and Wilkins, Deidre},
title = {Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {81},
number = {3},
pages = {634--644},
doi = {10.1093/cid/ciae596}
}
EUVIMED